235 related articles for article (PubMed ID: 27780331)
1. Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Cavedo E; Dubois B; Colliot O; Lista S; Croisile B; Tisserand GL; Touchon J; Bonafe A; Ousset PJ; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Galluzzi S; Delmaire C; Ceccaldi M; Girard N; Lehericy S; Duveau F; Chupin M; Sarazin M; Dormont D; Hampel H;
J Clin Psychiatry; 2016 Dec; 77(12):e1631-e1638. PubMed ID: 27780331
[TBL] [Abstract][Full Text] [Related]
2. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
[TBL] [Abstract][Full Text] [Related]
3. Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Teipel SJ; Cavedo E; Grothe MJ; Lista S; Galluzzi S; Colliot O; Chupin M; Bakardjian H; Dormont D; Dubois B; Hampel H;
Neuropharmacology; 2016 Sep; 108():128-35. PubMed ID: 26876309
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Kim GW; Kim BC; Park KS; Jeong GW
Sci Rep; 2020 Jul; 10(1):10912. PubMed ID: 32616841
[TBL] [Abstract][Full Text] [Related]
5. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
6. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
7. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging.
Petrella JR; Prince SE; Krishnan S; Husn H; Kelley L; Doraiswamy PM
AJNR Am J Neuroradiol; 2009 Feb; 30(2):411-6. PubMed ID: 19001543
[TBL] [Abstract][Full Text] [Related]
8. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
[TBL] [Abstract][Full Text] [Related]
9. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Teipel SJ; Drzezga A; Bartenstein P; Möller HJ; Schwaiger M; Hampel H
Psychopharmacology (Berl); 2006 Jul; 187(1):86-94. PubMed ID: 16767418
[TBL] [Abstract][Full Text] [Related]
10. An MRI substudy of a donepezil clinical trial in mild cognitive impairment.
Schuff N; Suhy J; Goldman R; Xu Y; Sun Y; Truran-Sacrey D; Murthy A
Neurobiol Aging; 2011 Dec; 32(12):2318.e31-41. PubMed ID: 20541841
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
12. Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Diaz-Galvan P; Lorenzon G; Mohanty R; Mårtensson G; Cavedo E; Lista S; Vergallo A; Kantarci K; Hampel H; Dubois B; Grothe MJ; Ferreira D; Westman E
Alzheimers Res Ther; 2023 Jun; 15(1):117. PubMed ID: 37353809
[TBL] [Abstract][Full Text] [Related]
13. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil.
Chapman SB; Weiner MF; Rackley A; Hynan LS; Zientz J
J Speech Lang Hear Res; 2004 Oct; 47(5):1149-63. PubMed ID: 15603468
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Homma A; Atarashi H; Kubota N; Nakai K; Takase T
J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
[TBL] [Abstract][Full Text] [Related]
17. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.
Yancheva S; Ihl R; Nikolova G; Panayotov P; Schlaefke S; Hoerr R;
Aging Ment Health; 2009 Mar; 13(2):183-90. PubMed ID: 19347685
[TBL] [Abstract][Full Text] [Related]
18. Fractionating the Rey Auditory Verbal Learning Test: Distinct roles of large-scale cortical networks in prodromal Alzheimer's disease.
Putcha D; Brickhouse M; Wolk DA; Dickerson BC;
Neuropsychologia; 2019 Jun; 129():83-92. PubMed ID: 30930301
[TBL] [Abstract][Full Text] [Related]
19. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
20. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E
Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
